Caliway Biopharmaceuticals (6919.TW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

6919.TW · Stock Price

TWD 101.00+29.50 (+41.26%)

Market Cap: $5.2B

Historical price data

Market Cap: $5.2BPipeline: 12 drugs (1 Phase 3)Patents: 9Founded: 2012HQ: Taipei, Taiwan

Sector Ranking#43 in Small Molecule Drugs

Overview

Caliway Biopharmaceuticals is a high-value, publicly traded biotech focused on developing breakthrough small-molecule drugs for aesthetic and chronic inflammatory conditions. Its core achievement is the development of CBL-514, a first-in-class injectable for localized fat reduction with a novel apoptosis mechanism, which has advanced into late-stage clinical trials. The company's strategy targets large, underserved markets where current treatments are inadequate, leveraging its proprietary platform and strategic base in Taiwan for global expansion.

Aesthetic MedicineMetabolic DiseaseDermatologyRheumatology

Technology Platform

Proprietary small-molecule platform designed to selectively induce adipocyte (fat cell) apoptosis through caspase-mediated pathways, enabling non-invasive, targeted fat reduction and potential metabolic benefits.

Pipeline

12

12 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
CBL-514 Injection	Subcutaneous Fat	Phase 3
CBL-514	Subcutaneous Fat	Phase 2
CBL-514 Injection	Subcutaneous Fat	Phase 2
CBL-514 injection	Cellulite	Phase 2
CBL-514 Injection	Subcutaneous Fat	Phase 2

Funding History

3

Total raised:$135M

IPO$60MUndisclosedJan 30, 2024

Series B$50MTaiwan Development FundDec 15, 2022

Series A$25MTaiwan Development FundJun 15, 2021

Opportunities

Caliway's lead asset, CBL-514, addresses a multi-billion dollar global market for non-invasive body contouring as a first-in-class pharmacological injectable.

Significant additional opportunity exists in combining with GLP-1 weight-loss drugs to address fat redistribution and skin laxity, potentially tapping into the massive obesity therapeutics market.

Risk Factors

The company faces extreme clinical and regulatory risk as its extraordinary valuation hinges on the success of a single, late-stage program.

Navigating U.S.

FDA approval for a first-in-class aesthetic drug is a major hurdle, and commercial success is not guaranteed in a competitive market dominated by established medical device companies.

Competitive Landscape

In localized fat reduction, Caliway's primary competitors are device-based (e.g., Allergan's CoolSculpting). In metabolic disease, it seeks a complementary role to systemic GLP-1 drugs from Novo Nordisk and Eli Lilly rather than direct competition. For rare conditions like Dercum's Disease, it faces little to no direct pharmacological competition.